AstraZeneca (LSE:AZN) has completed its previously announced exclusive licence agreement with Dizal Pharmaceutical Co., acquiring worldwide rights to develop and commercialise Zegfrovy (sunvozertinib).
The drug is an oral irreversible EGFR inhibitor used in non-small cell lung cancer (NSCLC), the most common form of lung cancer, accounting for 80-85% of cases.
AstraZeneca will pay Dizal $600m upfront, plus up to $900m tied to development, regulatory and sales milestones, alongside tiered royalties on global Zegfrovy sales.
The company said the transaction does not affect its 2026 financial guidance.
Zegfrovy is already approved in the US and China for patients with EGFR exon 20 insertion mutation-positive NSCLC whose disease progressed after platinum-based chemotherapy.
A supplemental application for use in the first-line setting has been accepted by the US Food and Drug Administration, backed by positive Phase III data from the WU-KONG28 trial presented at the 2026 American Society of Clinical Oncology meeting and published in The New England Journal of Medicine.
A parallel filing is under review by China's Center for Drug Evaluation.
Both regulators have granted Zegfrovy Breakthrough Therapy Designation for the first-line indication.
The deal extends AstraZeneca's existing lung cancer portfolio, which includes Tagrisso, Imfinzi and Enhertu, as the company builds out its EGFR-targeted treatment options ahead of the first-line regulatory decisions.
News Intelligence what this means for the company
AstraZeneca has completed its $1.5bn acquisition of Zegfrovy from Dizal Pharmaceutical, paying $600m upfront with up to $900m in milestone payments. The oral EGFR inhibitor is already approved in the US and China for a specific lung cancer mutation, with a supplemental application pending for first-line use backed by positive Phase III data. The deal does not affect AstraZeneca's 2026 financial guidance, and extends its existing lung cancer portfolio alongside Tagrisso, Imfinzi and Enhertu.
The acquisition adds a late-stage asset with regulatory momentum in a core oncology area, but the deal's immateriality to 2026 guidance and the upfront payment's modest scale relative to AstraZeneca's balance sheet suggest this is portfolio expansion rather than a transformative move. Success depends on the first-line regulatory decisions now pending with the FDA and China's Center for Drug Evaluation.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
